- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06119464
Re-Purposing the Ordering of 'Routine' Laboratory Tests in Hospitalized Medical Patients (RePORT Study)
Study Overview
Status
Conditions
Detailed Description
Background: Laboratory and Pathology testing contributes to rising health care expenditure. A relatively large percentage (up to 42%) of laboratory testing can be considered wasteful. Redundant testing alone has been estimated to waste up to 5 billion dollars annually in the United States of America. Laboratory over-utilization leads to false positives that promotes further inappropriate testing and procedures, interruption of normal sleep pattern of inpatients, as well as iatrogenic anemia and pain. A Canadian study showed significant hemoglobin reductions as a result of phlebotomy. Studies support the safe reduction of repetitive laboratory testing without negative effects on adverse events, readmission rates, critical care utilization, or mortality.
The aim of this research study is the following:
- To implement a multimodal intervention bundle containing healthcare provider and patient engagement tools for hospitalized medical inpatients in 14 hospitals across the province of Alberta in Canada using a cluster randomized stepped-wedge design
- To evaluate the impact of the intervention bundle on laboratory test utilization of six target laboratory tests (complete blood count, electrolytes, creatinine, urea, partial thromboplastin time, and international normalized ratio), costs, and patient safety outcomes.
This intervention bundle will be implemented across all the adult hospital sites in Alberta starting January 2023 and evaluated until October 2024.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- University of Calgary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- all participants (patients and healthcare providers) within enrolled adult hospitals in Alberta of medical and hospitalist units during study period
Exclusion Criteria:
- outside of the above-mentioned province
- hospitals not enrolled
- non-medical units (eg. ICU, surgical, pediatric, obstetrical units)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Unexposed to intervention (control period)
This is the time period of the study where hospital clusters are not receiving the intervention
|
|
|
Experimental: Exposed to intervention (intervention period)
This is the time period of the study where hospital clusters are receiving the multimodal intervention.
|
The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of routine laboratory tests ordered per patient-day in the intervention versus control periods
Time Frame: 1 year 9 months
|
Number of the six target laboratory tests (complete blood count, electrolytes, creatinine, urea, international normalized ratio and partial thromboplastin time) ordered per patient-day
|
1 year 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Costs associated with routine and all common laboratory test ordered
Time Frame: 1 year 9 months
|
Costs of test and associated costs with and without intervention
|
1 year 9 months
|
|
Proportion of hospital patient lab-free days
Time Frame: 1 year 9 months
|
Number of hospital patient-days not associated with laboratory blood draws
|
1 year 9 months
|
|
Proportion of critically abnormal test results
Time Frame: 1 year 9 months
|
As defined by lab standards, we will track the proportion of critically abnormal test results
|
1 year 9 months
|
|
Length of stay
Time Frame: 1 year 9 months
|
Patient length of stay on the unit
|
1 year 9 months
|
|
Transfer to Intensive Care Unit
Time Frame: 1 year 9 months
|
Transfer rate to Intensive Care Unit
|
1 year 9 months
|
|
In-patient and 30-day patient mortality over study period
Time Frame: 30 days post discharge
|
Mortality rate in hospital and at 30-days post discharge
|
30 days post discharge
|
|
30-day post discharge readmission rate
Time Frame: 30 days post discharge
|
Hospital re-admission within 30 days post discharge
|
30 days post discharge
|
|
Number of all common laboratory tests
Time Frame: 1 year 9 months
|
Number of all common laboratory tests (tests that contribute to >80% of hospital laboratory test utilization during study period) per patient-day.
|
1 year 9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anshula Ambasta, University of Calgary
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB17-1215
- H22-03005 (University of British Columbia)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Utilization, Health Care
-
Finnish Institute for Health and WelfareCompletedHealth Behavior | Health Care Utilization | Health Care Seeking BehaviorFinland
-
Children's Hospital Medical Center, CincinnatiCompletedEffect of Varied Outreach Methods on Appointment Scheduling and Appointment Completion Using MyChartHealth Care UtilizationUnited States
-
Seattle Children's HospitalCompleted
-
Harvard Medical School (HMS and HSDM)Brigham and Women's Hospital; Cambridge Health AllianceCompleted
-
Ludwig Boltzmann Institute for Digital Health and...Salzburger LandesklinikenCompleted
-
Children's Mercy Hospital Kansas CityUniversity of Missouri, Kansas CityCompletedHealth Care UtilizationUnited States
-
Children's Mercy Hospital Kansas CityCompleted
-
Geisinger ClinicCompleted
-
Ondokuz Mayıs UniversityCompletedHealth Care Utilization | MenTurkey
Clinical Trials on Multimodal Intervention: Education
-
Chinese University of Hong KongCompletedMild Cognitive ImpairmentHong Kong
-
Mogens Berg LaursenAarhus University Hospital; University of Southern DenmarkCompletedPatellofemoral Pain SyndromeDenmark
-
University of CadizCompletedHealth Literacy | Nursing Students | CompetenceSpain
-
University of BarcelonaHector Beltran-Alacreu, PhDCompletedPain | Osteo Arthritis Knee | Knee Arthroplasty | CatastrophizingSpain
-
Kahramanmaras Sutcu Imam UniversityCompletedFalls (Accidents) in Old Age | Malnutrition Elderly | Depression in Adults | Post-Traumatic Stress Disorder in Old Age | Frailty at Older AdultsTurkey (Türkiye)
-
University of MalagaAndaluz Health ServiceCompletedPhysical Activity | Dietary Modification | Patient Fall | Fragility | Multimodal Intervention | Other Metabolic DiseasesSpain
-
Finnish Institute for Health and WelfareKarolinska Institutet; Medical University of Vienna; University Of Perugia; Maastricht... and other collaboratorsCompletedCognitive Impairment | Dementia | Cognitive DeclineSweden, Austria, Finland, Italy
-
University Hospital, BordeauxCompletedMultiple System AtrophyFrance
-
University of MalagaCompleted